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a b s t r a c t
Background: Measles supplementary immunization activities (SIAs) are vaccination campaigns that sup-
plement routine vaccination programs with a recommended second dose opportunity to children of dif-
ferent ages regardless of their previous history of measles vaccination. They are conducted every 2–4
years and over a few weeks in many low- and middle-income countries. While SIAs have high vaccination
coverage, it is unclear whether they reach the children who miss their routine measles vaccine dose.
Determining who is reached by SIAs is vital to understanding their effectiveness, as well as measure pro-
gress towards measles control.
Methods: We examined SIAs in low- and middle-income countries from 2000 to 2014 using data from the
Demographic and Health Surveys. Conditional on a child’s routine measles vaccination status, we exam-
ined whether children participated in the most recent measles SIA.
Results: The average proportion of zero-dose children (no previous routine measles vaccination defined
as no vaccination date before the SIA) reached by SIAs across 14 countries was 66%, ranging from 28% in
São Tomé and Príncipe to 91% in Nigeria. However, when also including all children with routine measles
vaccination data, this proportion decreased to 12% and to 58% when imputing data for children with vac-
cination reported by the mother and vaccination marks on the vaccination card across countries. Overall,
the proportions of zero-dose children reached by SIAs declined with increasing household wealth.
Conclusions: Some countries appeared to reach a higher proportion of zero-dose children using SIAs than
others, with proportions reached varying according to the definition of measles vaccination (e.g., vacci-
nation dates on the vaccination card, vaccination marks on the vaccination card, and/or self-reported
data). This suggests that some countries could improve their targeting of SIAs to children who miss other
measles vaccine opportunities. Across all countries, SIAs played an important role in reaching children
from poor households.
 2017 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
At the turn of the 21st century, measles was the leading cause of
vaccine-preventable child mortality, with an estimated global mor-
tality burden of 535,000 deaths in the year 2000 [1]; it was then a
leading cause of death among post-neonates, causing 4–5% of
deaths in this age group [2]. While substantial progress to reduce
measles mortality has been made in recent years, measles still
caused an estimated 115,000 deaths globally in 2014 [3]. Despite
the availability of a safe and effective vaccine, routine vaccination
programs worldwide only reached approximately 85% of children
under the age of one with the first dose of the measles vaccine in
2014 [3]. This coverage also varies by region, ranging from a low
average of 83% in the World Health Organization (WHO) African
Region to a high average of 93% in the Americas Region [4]. Routine
measles vaccination coverage decreases further with the recom-
mended second dose to approximately 35% for children under
two and 53% at older ages globally [3,5]. WHO recommends that
all countries include a second routine dose of measles-containing
vaccine (MCV) [6]. However, in practice, the second dose of MCV
is offered through routine vaccination programs, supplementary
immunization activities (SIAs), or both. The administration of the
second dose of measles vaccine can vary by type of delivery and
recommended age of vaccination according to health system
infrastructure and measles endemicity. Countries with high levels
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of vaccination coverage, typically due to strong health systems,
rely on routine services for delivery, whereas countries with low
levels of coverage use SIAs to close the gaps in target coverage from
the routine program [6]. In order to supplement those routine vac-
cination efforts, organizations such as the Measles & Rubella Initia-
tive (partners including the American Red Cross, the United
Nations Foundation, the U.S. Centers for Disease Control and
Prevention, UNICEF and the WHO) and Gavi, the Vaccine Alliance,
currently provide support and co-financing for measles SIAs every
two to four years in low- and middle-income countries. SIAs are
mass campaigns lasting up to three weeks during which health
workers provide vaccinations directly to targeted children, regard-
less of their history of vaccination [7–9]. However, despite this
widespread support, many countries have still not achieved the
WHO target of a 95% reduction in measles mortality between
2000 and 2015 [3].
In order to achieve the current goal of eliminating measles in at
least five of the six WHO regions by 2020 [10], efforts must focus
both on strengthening the routine vaccination program and
addressing missed measles vaccination opportunities in the rou-
tine program through SIAs to achieve the necessary very high
levels of measles vaccination coverage required for population
immunity [11]. Achieving high levels of vaccination coverage
necessitates effective implementation of SIAs in countries that con-
tinue to experience high measles burden, with the success of these
campaigns contingent upon high coverage of target populations
likely to be missed by the routine vaccination program [12].
In this respect, measuring the overlap between routine measles
vaccination coverage and measles SIAs is necessary to ensure the
accurate estimation of the impact of countries’ full vaccination pro-
gram, which can subsequently help policymakers in the selection
between routine and SIA strategies for the second dose of measles
vaccine to establish effective measles control. In addition, the low-
est measles vaccination coverage and greatest risk of measles mor-
tality are often concentrated in populations that are the most
marginalized and disadvantaged economically [13]. Hence ensur-
ing equitable coverage of measles vaccination is a further objective
of SIAs.
Despite the widespread implementation of SIAs, marginalized
populations that are not vaccinated through routine health ser-
vices are often missed in vaccination campaigns, requiring addi-
tional efforts to serve these hard-to-reach populations [14–16]. A
key question regarding coverage of marginalized populations is
the degree to which current SIA outreach efforts have proven to
be effective. To what extent are the children targeted and covered
by measles SIAs previously unvaccinated and what are the charac-
teristics of these children, as compared to those covered by the
routine vaccination program? In other words, how many and what
children who have not previously received a measles vaccine dose
are reached by SIAs? Our analysis aims to address these questions
using Demographic and Health Survey (DHS) data.
2. Methods
The analysis focused on low- and middle-income countries (as
classified by the World Bank) for which years and dates of SIAs
were available from the WHO [17,18]. A full list of all the countries
with measles SIAs reviewed is included in the Supplementary
appendix (Table A). We relied on DHS data to determine the rou-
tine and SIA vaccination status of children. The DHS are nationally
representative household-based surveys conducted periodically in
more than 90 countries [19]. Each country survey includes a vacci-
nation history for children under 5 years of age at the time of the
survey. The interviewing approach of the DHS, which reconstructs
the child’s history of vaccination according to the child’s health
card and/or maternal reports of prior vaccination, is currently the
best practice to determine the proportion of children covered by
each vaccine at the time of the survey [20]. Specifically, for routine
vaccination, if the health card of the child is available, DHS inter-
viewers ask to see the card and transcribe the dates of each vacci-
nation recorded on the card and also ask if the child has obtained
other vaccinations that are not recorded. If the card is not available,
interviewers ask the mother/guardian whether the child has
received doses of each vaccine at any time before the survey,
and, if so, how many doses [21].
We first examined the schedule of SIAs in the identified coun-
tries from 2000 to 2014 [18]. We then selected available survey
years from the DHS that occurred one to two years following
measles SIAs [22]. The survey data was inspected for availability
of the ‘‘vaccinated during campaign” indicator, in order to deter-
mine if SIA (campaign) vaccination status was included in addi-
tion to routine vaccination status during the administration of
the survey. In the included surveys, mothers were asked whether
their children participated in a specific SIA (with possible
answers being ‘‘yes”, ‘‘no”, or ‘‘don’t know”) for which the date
of implementation was available [18]. While the mother/guardian
is asked if additional doses not included on the vaccination card
were received as described above, we do not rely on this
question to classify children as vaccinated through routine or
SIA, but instead we have only selected surveys where specific
questions about SIAs are asked. Data included both routine and
SIA vaccination status, child age at time of vaccination, and
household wealth quintile. We also estimated the 95% confidence
intervals (CIs) using a logit transform for the proportion of
children receiving routine measles vaccination for each country
in the analysis [23].
In order to estimate the proportion of children reached for each
measles vaccination campaign among children with no previous
history of vaccination, we first examined these children according
to whether or not they were covered by the most recent measles
SIA prior to the survey round in the DHS-derived dataset. We then
examined the routine vaccination status of the children, according
to the child’s vaccination card. There are several approaches to
defining receipt of routine measles vaccination prior to the SIA
with this dataset, including utilizing vaccination card information,
either dates or check marks, and self-reported data. Of the children
who reported routine measles vaccination coverage (MCV1) in the
DHS dataset, approximately 55.6% have vaccination dates on their
vaccination card, approximately 43.7% have self-reported vaccina-
tion, and 0.7% have marks on the vaccination card. Our preference
in this analysis was to identify children with a measles vaccination
date marked on the vaccination card prior to the initial date of the
measles SIA, i.e. children with a history of measles vaccination
prior to the SIA. This approach enabled us to estimate the propor-
tion of SIA doses that reach children with no prior doses of measles
vaccine (i.e., ‘‘zero-dose children”) before the initial date of the SIA.
In order to estimate this proportion, for each scenario, the denom-
inator was the number of children under five years of age reported
as receiving a specific SIA measles vaccine. The numerator varied
according to the definition of routine measles vaccination prior
to the SIA within this dataset in order to find the children who
received both measles SIA and routine vaccines, as described
above.
The probability of reaching zero-dose children with measles
SIAs was subsequently measured by household wealth quintile,
according to the DHS wealth index defined as: poorest, poorer,
middle, richer, richest [22]. We then tested for ‘‘trend” of SIA vac-
cination status by wealth quintile, relying on Cuzick’s nonparamet-
ric test for trend across ordered groups in STATA [24]. Additionally,
we examined how SIAs might improve population immunity using
standardized assumptions for vaccine efficacy: 85% for the first
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dose of measles vaccine before one year of age and 98% for the sec-
ond dose at age one year or later [25–27].
We also compared two additional scenarios. First, we examined
the proportion of zero-dose children including all children with
routine measles vaccination, including those with vaccination date
on the vaccination card, vaccination reported by mother, or vacci-
nation marked on the vaccination card. Second, we examined the
proportion of zero-dose children using imputed binary values (0
= zero-dose at time of SIA, 1 = already routinely vaccinated at time
of SIA) for vaccination reported by mother and vaccination marked
on the vaccination card. For the latter scenario, we rely on the mul-
tiple imputation (mi) command of a logistic regression in STATA
and averaged over ten imputations. Multiple imputation utilizes
the distribution of the observed data to correctly reproduce the
variance/covariance matrix that would have been observed in a
dataset without missing values [28,29]. Using the weights pro-
vided with the DHS datasets, we also obtained a representative
sample of children in order to better compare the estimated SIA
coverage with routine measles vaccination coverage.
Finally, in a simple attempt to understand country determi-
nants, we conducted further statistical analysis to examine what
might be possible determinants of the estimated proportions of
zero-dose children reached, using multivariate linear regression
to analyze the impact of covariates relevant to the country con-
texts. These analyses were conducted at the country level. We
examined the correlations between covariates and tested the
covariates for significance at the 5% level (p-value < 0.05) both
individually (with likelihood ratio testing) and as a set (with a
nested models F-test). The examined covariates included MCV1,
gross domestic product (GDP) per capita, population density, per-
centage of population in urban areas, health care expenditure per
capita, WHO region, and World Bank income level. We included
MCV1 coverage under the hypothesis that countries with lower
MCV1 coverage might be more likely to have zero-dose children
reached by SIAs. The remaining covariates were ones that would
likely be associated with the accessibility and strength of the
health system, which would also impact the numbers of
zero-dose children. All analyses were implemented using STATA,
version 12.
3. Results
The comparison of the schedule of SIAs and available survey
years from DHS yielded 49 potential countries with measles SIAs
that occurred one to two years prior to the survey from an initial
set of 111 countries with both measles SIA and DHS data available
(Fig. 1) [18,22]. Following examination of this DHS data, 14 coun-
tries and 15 survey-years were identified with campaign vaccina-
tion information. The final 14 countries included in the analysis
had DHS surveys ranging from 2002 to 2008. The full details of
the relevant measles SIAs conducted are presented in Table 1.
The unweighted sample size of children both reached by the
measles SIA and covered by the DHS ranged from 121 in Haiti to
9620 in Indonesia. When restricting to children who received both
a routine and SIA dose, the unweighted range changes to: (1) 108–
7505 without exclusions; (2) 46–1500 excluding self-reported rou-
tine vaccination; and (3) 31–1330 including only children with a
measles vaccination date on their vaccination card. Table 2 pro-
vides the full range of sample sizes included in the analysis. Among
these children, prior receipt of measles vaccine in the routine pro-
gram was defined as having a date of measles vaccination on their
vaccination card prior to the initial date of the measles SIA. For
these children, the proportion of zero-dose children reached ran-
ged from 28% (95% CI: 25–31%) in São Tomé and Príncipe to 91%
(90–93%) in Nigeria. While not regionally representative, the two
countries from the Americas, Haiti and Honduras, are nearly equal
at 51% (43–60%) and 53% (51–55%), respectively; while Indonesia,
as the lone country from Southeast Asia reaches approximately
86% (85–87%) zero-dose children with SIAs (Table 2).
However, in the first scenario analysis, if vaccination reported
by mother or marked on the vaccination card without a date was
included, the proportion of zero-dose children reached by SIAs
decreased to 12% overall, from as low as 1% (95% CI: 0–5%) in Hon-
duras up to 22% (20–24%) in Indonesia (Table 3). In the second sce-
nario analysis, relying on multiple imputation to simulate the self-
reported data, the proportion of zero-dose children reached lay in
between the base case analysis and the first scenario analysis at
58% overall. The proportion of zero-dose children reached ranged
from 27% (20–34%) in São Tomé and Príncipe to 86% (86–87%) in
Nigeria. We also show that the children in the DHS who do and
do not receive SIA vaccination do not drastically differ by the type
of routine measles vaccination data (Supplementary appendix,
Table B). In the Supplementary appendix (Table C), we included
an analysis of the maternal age, maternal education, wealth quin-
tile, and percent of households in urban areas for those with and
without a vaccination date on their vaccination card.
Fig. 2 presents results for the proportion of zero-dose children
reached with SIAs by household wealth quintile in each country.
Generally, the proportions of zero-dose children reached declines
with increasing wealth, with those from the poorest households
being more likely to be reached by the SIA than those from the
richest households. For example, in Burkina Faso, the SIA was
92% (95% CI: 88–95%) likely to reach zero-dose children from the
poorest households while only 64% (60–67%) likely to reach chil-
dren from the richest households; whereas, in the Democratic
Republic of the Congo, the proportion ranged from 93% (89–97%)
in the poorest to 85% (81–88%) in the richest. In testing for ‘‘trend”
of SIA vaccination status by wealth quintile, we found a lack of
trend in the majority of countries, indicating non-discriminatory
SIAs. However, we found a significant trend that SIA vaccination
declines with increasing wealth in Burkina Faso, Guinea, Haiti,
Indonesia, and Niger, suggesting that SIAs in these countries would
be pro-poor (Supplementary appendix, Table D). No country had a
significant trend in which SIA vaccination increased with increas-
ing wealth.
Across the 14 countries in the analysis, SIAs could improve
population immunity by 4% (95% CI: 3–5%) when defining measles
vaccination as having a measles vaccination date on the
vaccination card prior to the initial date of the measles SIA. When
the definition is expanded to include vaccination reported by
mother or marked on the vaccination card without a date, this
improvement could increase to 11% (10–12%) (Supplementary
appendix, Table E).
In the country determinants analysis, none of the examined
covariates – routine measles vaccination coverage, GDP per capita,
health care expenditure per capita, population density, percentage
of population in urban areas – were statistically significant in the
prediction of the proportion of zero-dose children reached in the
model (Table 4).Fig. 1. Selection of the countries included in the analysis.
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The correlation between the proportion of zero-dose children
reached and each covariate is generally low, with correlation coef-
ficients ranging between 0.2 and 0.4, and insignificant. How-
ever, the proportion of zero-dose children reached and routine
measles vaccination coverage were moderately correlated at
0.50 (95% CI: 0.80 to 0.02), indicating near significance at the
5% level (p-value = 0.06).
4. Discussion
We examined the probability that measles SIAs reached chil-
dren with no previous history of measles vaccination in fourteen
low- and middle-income countries. Specifically, we found, in our
base case scenario (defining measles vaccination as a measles vac-
cination date marked on the vaccination card prior to the initial
date of the measles SIA) that the proportion of zero-dose children
– children with no prior doses of measles vaccine – reached by SIAs
ranged from a low 28% (95% CI: 25–31%) in São Tomé and Príncipe
to a high 91% (90–93%) in Nigeria (Table 2). Yet, recall the findings
of the two scenario analyses, which showed a range of 1% (0–5%) in
Honduras up to 22% (20–24%) in Indonesia in scenario one (adding
vaccination marks on the vaccination card and vaccination
reported by the mother to the definition of measles vaccination)
and a range of 27% (20–34%) in São Tomé and Príncipe to 86%
(86–87%) in Nigeria in scenario two (imputing routine measles
Table 1
Details of measles supplementary immunization activities (SIAs) by country.
Country WHO region Gross domestic product
per capita (2015 US$)
SIA year DHS survey year
Benin AFRO $780 2005 2006
Burkina Faso AFRO $620 2001 2003
Democratic Republic of the Congo AFRO $480 2007 2007
Ghana AFRO $1360 2001 2003
2002
Ghana AFRO $1360 2006 2008
Guinea AFRO $550 2002 2005
2003
Haiti AMRO $810 2001 2005
2002
Honduras AMRO $2330 2004 2005
Indonesia SEARO $3340 2002 2002
2002
Kenya AFRO $1350 2002 2003
Lesotho AFRO $1070 2000 2004
2003
Niger AFRO $360 2004 2006
2005
Nigeria AFRO $2660 2005 2008
2006
São Tomé and Príncipe AFRO $1630 2007 2008
Sierra Leone AFRO $590 2003 2008
2006
DHS = Demographic and Health Survey. WHO =World Health Organization. AFRO =WHO Regional Office for Africa; AMRO =WHO Regional Office for the Americas; SEAR-
O = WHO Regional Office for Southeast Asia.
Sources: Demographic and Health Surveys (DHS) [22]; World Health Organization [18]; World Bank [33].
Note: Only DHS data was used in this analysis, but World Health Organization and World Bank indicators were obtained for descriptive context.
Table 2
Measles supplementary immunization activities (SIA) proportions of zero-dose children reached (95% confidence intervals in parentheses) – base case scenarioa.
Country DHS survey year Number of children with
immunization data
Number of children
who received SIA
measles vaccine
Number of children who
received both measles SIA
and routine vaccinesb
Proportion of zero-dose
children reached with SIA
Benin 2006 8331 3000 908 70% (68–72%)
Burkina Faso 2003 3936 143 31 78% (70–86%)
Democratic Republic of the Congo 2007 4798 1898 221 88% (87–90%)
Ghana 2003 2608 1722 863 50% (48–52%)
Ghana 2008 1502 535 243 55% (51–59%)
Guinea 2005 2398 1220 479 61% (58–63%)
Haiti 2005 673 121 59 51% (43–60%)
Honduras 2005 6443 1788 841 53% (51–55%)
Indonesia 2002 11,939 9620 1330 86% (85–87%)
Kenya 2003 3527 1464 444 70% (67–72%)
Lesotho 2004 1989 760 342 55% (52–59%)
Niger 2006 4176 2425 710 71% (69–73%)
Nigeria 2008 7100 1713 148 91% (90–93%)
São Tomé and Príncipe 2008 1333 614 442 28% (25–31%)
Sierra Leone 2008 2190 1222 219 82% (79–85%)
DHS = Demographic and Health Survey.
Note: ‘‘Zero-dose children” are defined as children with no previous history of measles vaccination.
a Unweighted sample sizes including only children who would have had the opportunity to be eligible for both SIA and routine vaccination prior to the SIA according to the
WHO recommendation for routine measles vaccination at 9 months of age.
b Routine measles vaccination with vaccination date on card prior to the initial date of the measles SIA.
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vaccination for vaccination marks on the vaccination card and vac-
cinated reported by the mother).
We also found that the proportion of zero-dose children
reached by SIAs declined with increasing wealth on average,
although these equity improvements were not seen in each coun-
try. In São Tomé and Príncipe, in our base case scenario, this pro-
portion ranged from 28% (18–37%) in the poorest wealth quintile
to 30% (22–37%) in the highest wealth quintile; while in Nigeria,
the proportion ranged from 98% (95–100%) in the poorest wealth
quintile to 85% (83–87%) in the highest (Fig. 2).
This analysis examined how SIAs would strengthen measles
control efforts and achieve their objective by identifying the
zero-dose children reached compared with those children previ-
ously reached by routine vaccination efforts. This enables better
assessment of the ‘‘real-world” impact of routine vaccination and
SIA efforts in achieving the worldwide goals of measles control
and elimination. In order to examine the probability of reaching
zero-dose children, we defined SIA vaccination in the analysis as
children with the vaccination date prior to the date of the SIA
included on their vaccination card, as we had the greatest confi-
dence of true MCV1 coverage with this approach. The ensuing pro-
portion of zero-dose children reached is likely to be an
overestimate, as children with the self-report of the mother or a
mark on their vaccination card might also have received a routine
vaccination prior to the campaign.
Therefore, we also examined the proportion of zero-dose chil-
dren reached for all data types – vaccination date on the vaccina-
tion card, vaccination reported by mother, or vaccination marked
on the vaccination card – as well as an imputation of vaccination
reported by mother and vaccination marked on the vaccination
card in scenario analyses (Table 3). In the first scenario analysis,
we found that the proportion of zero-dose children reached by SIAs
was much lower than the proportions in the primary analysis (12%
vs. 66%), while the imputation showed a proportion of zero-dose
children reached closer to that of the primary analysis (58% vs.
66%). While the first scenario analysis might overestimate MCV1
coverage, self-reported data is included in current estimates of rou-
tine measles vaccination coverage [30] and, therefore, it may be a
more accurate reflection of the true overlap between routine and
SIA vaccination efforts. However, there is inherent uncertainty in
the data for children with a vaccination mark on the card (0.7%
of data set) or self-reported data (43.7% of data set) [31]. Without
a vaccination date provided, it is not clear whether a vaccination
mark indicates a routine vaccination that did indeed take place
before the SIA or whether a self-reported vaccination was received
via routine vaccination or via measles SIA. Despite this uncertainty,
the first scenario analysis provides a lower bound for the propor-
tion of zero-dose children reached if all children reporting measles
vaccination in the DHS are included. Additionally, it is important to
note that the children who are and are not reached by SIA vaccina-
tion in the DHS do not drastically differ by the type of routine
measles vaccination data (Supplementary appendix, Table B). In
other words, the children reached by SIAs are not necessarily more
or less likely to have a vaccination date on their vaccination card
than the children who were not reached. Furthermore, the propor-
tion of zero-dose children reached with SIAs by household wealth
quintile similarly declines with increasing wealth when self-
reported data is included (Supplementary appendix, Fig. F), indi-
cating that any differences of having vaccination cards by wealth
quintile do not affect the general distributional impact of SIAs.
However, there may be demographic differences between chil-
dren with a date on their vaccination card compared to those with-
out, indicating that access might be affecting the numbers of zero-
dose children. In the Supplementary appendix (Table C), we
included an analysis of the maternal age, maternal education,
wealth quintile, and percent of households in urban areas for those
with and without a vaccination date on their vaccination card. The
percentage of households in urban areas does not appear to have a
consistent relationship with the percentage of children with a vac-
cination date on their vaccination card, with 47% of countries hav-
ing a greater percentage of households in urban areas among those
with a vaccination date on their card compared to 43% of countries
where there is a greater percentage among those without a vacci-
nation date. While mean maternal age and mean years of maternal
education do not differ by more than 7%, there are larger differ-
ences for mean wealth quintile for some countries. For mean
wealth quintile, seven countries differ by less than 5%, six countries
differ by less than 15%, and two countries (Niger and Nigeria) differ
by 23% and 28%. Therefore, as we might expect, there appears to be
differences in households being able to access routine health ser-
vices according to wealth, borne out by the analyses of distribu-
tional impact of SIAs.
We observed a range of proportions of zero-dose children
reached by measles SIAs among the countries in this analysis, with
some seemingly more effective at selective targeting than others,
depending on the definition of measles vaccination being utilized
Table 3
Scenario analyses of measles supplementary immunization activities (SIA) proportions of zero-dose children reached (95% confidence intervals in parentheses).
Country DHS survey year Proportion of zero-dose children reached with SIA
Base casea Scenario analysis 1b Scenario analysis 2c
Benin 2006 70% (68–72%) 19% (15–22%) 67% (65–69%)
Burkina Faso 2003 78% (70–86%) 20% (3–36%) 73% (66–79%)
Democratic Republic of the Congo 2007 88% (87–90%) 11% (8–15%) 82% (81–83%)
Ghana 2003 50% (48–52%) 11% (7–15%) 39% (36–43%)
Ghana 2008 55% (51–59%) 4% (0–12%) 37% (33–41%)
Guinea 2005 61% (58–63%) 17% (10–22%) 32% (29–34%)
Haiti 2005 51% (43–60%) 11% (0–30%) 48% (41–55%)
Honduras 2005 53% (51–55%) 1% (0–5%) 34% (32–36%)
Indonesia 2002 86% (85–87%) 22% (20–24%) 75% (74–76%)
Kenya 2003 70% (67–72%) 13% (8–18%) 57% (55–59%)
Lesotho 2004 55% (52–59%) 3% (1–10%) 39% (36–43%)
Niger 2006 71% (69–73%) 16% (12–20%) 69% (67–71%)
Nigeria 2008 91% (90–93%) 15% (10–18%) 86% (86–87%)
São Tomé and Príncipe 2008 28% (25–31%) 6% (0–11%) 27% (20–34%)
Sierra Leone 2008 82% (79–85%) 12% (6–18%) 68% (65–71%)
DHS = Demographic and Health Survey.
Note: ‘‘Zero-dose children” are defined as children with no previous history of measles vaccination.
a Measles vaccination defined as a measles vaccination date marked on the vaccination card prior to the initial date of the measles SIA.
b Routine measles vaccination includes vaccination date on card, vaccination reported by mother, or vaccination marked on card.
c Routine measles vaccination includes vaccination date on card and imputed values for vaccination reported by mother and vaccination marked on card.
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(e.g., vaccination dates on the vaccination card, vaccination marks
on the vaccination card, and/or self-reported data). It is likely that
countries with relatively low coverage for measles in the routine
vaccination program, such as Nigeria, might have higher propor-
tions of zero-dose children reached. In fact, Nigeria has the lowest
MCV1 coverage of the countries in our analysis at 43% around the
years of its SIA (2005–6) [4]. In Table 5, we compare the weighted
SIA coverage using the weights provided with each DHS dataset
with MCV1 coverage. If we assume a representative sample using
these weights, given national SIAs, we can likewise estimate the
increase in measles coverage from SIAs (Table 5). We also exam-
ined the potential improvements in immunity levels due to SIAs,
finding a 4–11% increase in immunity from SIAs (Supplementary
appendix, Table E). However, this broad estimation has been com-
puted using standardized assumptions for vaccine efficacy (85% for
the first dose of measles vaccine and 98% for the second dose) as
DHS = Demographic and Health Survey. 
Note: “Zero-dose children” are defined as children with no previous history of measles vaccination, defined as a 
measles vaccination date marked on the vaccination card prior to the initial date of the measles SIA.
Fig. 2. Proportion of zero-dose children reached with supplementary immunization activities by household wealth quintile, in each of the countries studied (DHS survey year
is indicated in parentheses).
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country-level data is not available [25–27], which hides enormous
heterogeneity across and within countries. Vaccine efficacy is also
potentially reduced in the field as compared to facility-based rou-
tine settings, due to issues of climate, timeliness, and the quality of
the cold chain. Without additional serological testing, the true
immunity levels before and after SIAs remain uncertain [32]. More-
over, in countries with low routine vaccination coverage (at the
time of the survey), the role of immunity due to natural infection
may be more dramatic, such that the second dose of measles vac-
cine may not have as large of an impact as estimated in this
analysis.
The correlation coefficient between the SIA proportion of zero-
dose children reached and the routine measles first dose coverage
was indeed 0.50, and is nearly significant (0.06) despite the small
sample size. Meanwhile, in this analysis, the island nation of São
Tomé and Príncipe, with both high routine coverage (86% in the
year of the SIA) and a small population (less than 200,000), was
unlikely to reach zero-dose children with SIAs, which may be true
for other countries able to achieve a high level of routine coverage
[4,33]. Table G in the Supplementary appendix provides routine
coverage for MCV1 for the countries in this analysis from 2000 to
2014 [4].
Nevertheless, this analysis presents a number of limitations,
which complicate drawing generalizable conclusions from its find-
ings. First, the small sample size in the numbers of children with
measles SIA data collected in the DHS is a limiting factor. Second,
while information collected in DHS is subject to reporting and
recall biases (although evidence from Egypt suggests that mothers’
reports can be of high quality [20]), we relied on the approach of
estimating the proportion of zero-dose children reached with dates
copied from the vaccination card in order to counteract these
potential biases, but also pursued a number of additional scenario
analyses (Table 3). Moreover, as all scenarios analyzed utilize a
denominator derived from the DHS question on whether a ‘‘child
was vaccinated during campaign,” there is additional uncertainty
regarding the accuracy of the reported information, as it is simi-
larly subject to reporting and recall biases. As DHS surveys use
complex sampling and require weights for country-level estimates,
but the primary analysis is unweighted, the estimated proportions
may not be reflective of the proportion reached at the national
level, and do not indicate coverage. However, the country-level
weighted estimates in Table 5 do not greatly differ from the
unweighted proportions in Table 2, as the same DHS weights are
used to weight both the numerators and denominators to arrive
at the estimates in Table 5. In analyzing what might be the country
determinants of SIAs reaching zero-dose children, the lack of sig-
nificance of the country-level covariates tested (Table 4) suggests
that there would not be clear country-level predictors of success
in reaching zero-dose children. We further compared the propor-
tion of zero-dose children reached to routine measles vaccination
Table 4
Results of country-level determinants analysis of the proportion of zero-dose children reached with supplementary immunization activities.
Variable Coefficient Standard error Regression p-value Correlation coefficient Correlation p-value
Constant 1.078 0.287 0.01 N/A N/A
Routine measles immunization coverage 0.004 0.005 0.46 0.495 0.06
Gross domestic product per capita 0.001 0.001 0.91 0.210 0.45
Population density 0.001 0.001 0.68 0.310 0.26
Percent of urban population 0.004 0.006 0.54 0.417 0.12
Health care expenditure per capita 0.002 0.005 0.79 0.255 0.36
WHO Africa region fixed effect (reference)
WHO Americas region fixed effect 0.083 0.195 0.69 N/A N/A
WHO Southeast Asia region fixed effect 0.331 0.258 0.25 N/A N/A
Low-income country fixed effect (reference)
Lower middle-income country fixed effect 0.113 0.179 0.55 N/A N/A
WHO =World Health Organization. A full list of countries by WHO region is included in the Supplementary appendix (Table A).
Note: ‘‘Zero-dose children” are defined as children with no previous history of measles vaccination.
Table 5
Comparison of supplementary immunization activity (SIA) weighted coverage reaching zero-dose children with coverage of routine measles first dose (MCV1).
Country DHS survey year Weighted proportion of zero-dose
children reached with SIA (95% CI)
MCV1 coverage
during SIAa
Increase in measles vaccine
coverage after SIA (95% CI)b
Benin 2006 70% (68–72%) 61% 27% (26–29%)
Burkina Faso 2003 74% (64–83%) 63% 27% (18–37%)
Democratic Republic of the Congo 2007 89% (87–91%) 68% 28% (27–30%)
Ghana 2003 51% (49–54%) 78% 11% (9–14%)
Ghana 2008 53% (49–57%) 85% 8% (4–12%)
Guinea 2005 60% (57–63%) 47% 32% (29–35%)
Haiti 2005 47% (37–57%) 56% 21% (10–31%)
Honduras 2005 59% (56–61%) 92% 5% (2–7%)
Indonesia 2002 87% (86–88%) 72% 24% (23–26%)
Kenya 2003 66% (63–69%) 78% 15% (12–17%)
Lesotho 2004 56% (52–60%) 80% 11% (7–15%)
Niger 2006 79% (77–81%) 46% 43% (41–45%)
Nigeria 2008 90% (88–92%) 43% 51% (49–53%)
São Tomé and Príncipe 2008 20% (16–24%) 86% 3% (0–7%)
Sierra Leone 2008 83% (79–86%) 69% 26% (23–29%)
Note: ‘‘Zero-dose children” are defined as children with no previous history of measles vaccination.
a The year of MCV1 coverage listed is the year during which the SIA took place. Source: World Health Organization. (2015). WHO/UNICEF coverage estimates for
1980–2014. Geneva: WHO/UNICEF. Last updated: 4 November 2015.
b Assumes that the weighted SIA coverage addresses the current gap in MCV1 coverage, i.e., (1 – MCV1 coverage)*(Weighted proportion of zero-dose children reached
with SIA).
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coverage in the year of the SIA in order to confirm that there is
indeed a clear correlation between this outcome and MCV1
(Table 5). However, the lack of significance may also be due to
the small sample size of countries meeting our criteria for inclu-
sion in the study. As additional empirical evidence on the overlap
between routine and SIA delivery of measles vaccination becomes
available, this type of analysis should be re-examined. For example,
future research might include serosurveys using immunoassays
examining measles antibodies to compare the presence of measles
immunoglobulin before and after SIA rollout.
In prior analyses, SIAs have not only been shown to be effective
at providing a second opportunity for measles vaccination, but also
more equitable measles vaccination coverage by strengthening
coverage among children from lower socio-economic status
[21,34]. A previous analysis also found that the percentage of
zero-dose children vaccinated in SIAs declined with increasing
wealth, such that the largest proportions were from the poorest
households [34]. On the other hand, another analysis suggests that
SIAs are often biased towards those with previous high access to
vaccination, estimating an effective coverage level (i.e., proportion
of the remaining susceptible population immunized by the cam-
paign) up to 50% [35]. While these two analyses examine SIA
impact in a single country (Kenya and Malawi, respectively), this
analysis goes a step further in examining the impact across four-
teen low- and middle-income countries. Our analysis generally fol-
lows the former storyline, with the proportions of zero-dose
children reached being highest among the poorest households on
average. These results provide evidence of the impact of measles
SIAs overall leading to more equitable measles vaccination
coverage.
This research is also a starting point to examine what might be
the impact of ‘vertical’ delivery of specific health interventions on
the ‘horizontal’ delivery of primary and preventive services in the
health system, and the broader benefits and disadvantages of SIAs.
Our analysis shows improvements in measles coverage due to SIAs,
thus supplementing the efforts of routine vaccination, and
increases in equity by reaching children from poorer households.
But beyond the scope of our analysis and measles vaccination, pre-
vious work examining the impact of measles SIAs on the broader
health system have ranged from positive to negative associations
with system functioning [36–40]. For example, there remains the
potential for challenges to the health system if measles SIAs are
relied upon as a replacement for weak routine vaccination pro-
grams rather than as a supplementary improvement to routine
vaccination services. Some have recommended that SIAs must
have ‘‘reached, and sustained, a predetermined level” in order to
counteract the potential for these efforts to supplant or mask weak
routine vaccination programs [41]. Furthermore, others have pro-
posed that continued efforts towards measles control should focus
specifically on strengthening the routine vaccination program,
integrating vaccination with other health services, and encourag-
ing donor support of primary health care [42].
As decision-makers evaluate measles control decisions, the
ability to accurately demonstrate what future efforts are
needed for measles control will be critical. This research can
serve to elucidate some, but not all, of the uncertainty around
the SIA impact by providing information in specific country
contexts that can be used to evaluate measles control achieve-
ments. By estimating the real-world effectiveness of SIAs
reaching those children not always reached by routine health
systems, we can provide valuable insight into the estimation
of public health impact towards measles control and elimina-
tion. Additionally, this paper also highlights the important role
that SIAs can play in improving equity by increasing vaccina-
tion coverage beyond routine levels and reaching children from
poorer households.
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